Pharmacological evaluation of Ashwagandha highlighting its healthcare claims, safety, and toxicity aspects

Deepa S. Mandlik,Ajay G. Namdeo,Deepa S. Mandlik (Ingawale)
DOI: https://doi.org/10.1080/19390211.2020.1741484
2020-04-03
Journal of Dietary Supplements
Abstract:<span><i>Withania somnifera</i>, commonly known as "Ashwagandha" or "Indian ginseng" is an essential therapeutic plant of Indian subcontinent regions. It is regularly used, alone or in combination with other plants for the treatment of various illnesses in Indian Systems of Medicine over the period of 3,000 years. Ashwagandha (<i>W. somnifera</i>) belongs to the genus <i>Withania</i> and family <i>Solanaceae.</i> It comprises a broad spectrum of phytochemicals having wide range of biological effects. <i>W. somnifera</i> has demonstrated various biological actions such as anti-cancer, anti-inflammatory, anti-diabetic, anti-microbial, anti-arthritic, anti-stress/adaptogenic, neuro-protective, cardio-protective, hepato-protective, immunomodulatory properties. Furthermore, <i>W. somnifera</i> has revealed the capability to decrease reactive oxygen species and inflammation, modulation of mitochondrial function, apoptosis regulation and improve endothelial function. Withaferin-A is an important phytoconstituents of <i>W. somnifera</i> belonging to the category of withanolides been used in the traditional system of medicine for the treatment of various disorders. In this review, we have summarized the active phytoconstituents, pharmacologic activities (preclinical and clinical), mechanisms of action, potential beneficial applications, marketed formulations and safety and toxicity profile of <i>W. somnifera</i>.</span>
What problem does this paper attempt to address?